Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Kew, Kayleigh M ^a   Seniukovich, Alieksei ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Grodno Regional Clinical Hospital   (Belarus)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALMETEROL; VILANTEROL; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ADVERSE OUTCOME; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907423949     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010115.pub2     Document Type: Review

References (252)

1. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, et al.Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. Journal of Chronic Obstructive Pulmonary Disease 2009;6(5):320-9.
2. Dalal AA, Blanchette CM, Petersen H, St. Charles M. Cost-effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; 2009 May 15-20; San Diego. 2009:A1502 [Poster K54].
3. DiSantostefano RL, Li H, Rubin DB, Stempel DA. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013;3(4):e001838. [DOI: 10.1136/bmjopen-2012-001838].
4. GlaxoSmithKline. A Randomized, Double-Blind, Parallel-Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD). SCO100250. www.gsk-clinicalstudyregister.com/ (accessed 25 May 2013).
5. GlaxoSmithKline. A randomized, double-blind, parallel-group, 52-week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg bid with salmeterol DISKUS 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). www.gsk-clinicalstudyregister.com/ (accessed 8 April 2013).
6. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53(6):477-82.
7. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62(11):938-43.
8. Bale G, Martinez-Camblor P, Burge PS, Soriano JB. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine 2008;102(10):1468-72.
9. Bale GA, Burge PS, Burge C, Moore VC. The ISOLDE Study 11-13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster H42.
10. Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value In Health 2006;9(4):227-35.
11. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58(8):654-8.
12. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal 2000;320(7245):1297-303.
13. Burge S, Sondhi S, Williams MK, Wilson K, Efthimiou J. An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine 2000;161 Suppl 3:A491.
14. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58(8):659-64.
15. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124(4):1350.
16. D'Urzo AD, Calverley PMA. Withdrawal of treatment in the ISOLDE study [letter]. Chest 2004;125(6):2368.
17. GlaxoSmithKline F. A multi-centre, double-blind, placebo-controlled, parallel group study of the efficacy and tolerability of long-term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non-asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. FLTB3054. www.gsk-clinicalstudyregister.com/ (accessed 20 May 2013).
18. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine 1999;93(3):161-6.
19. Jebrak G. Corticosteroid therapy and chronic obstructive broncho-pneumopathies: the ISOLDE study. Presse Medicale 2000;29(16):1461-2.
20. Jones PW, Willits LR, Burge PS, Calverley PMA. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal 2003;21(1):68-73.
21. Marchand E. Withdrawal from and study design of the ISOLDE trial [comment]. Chest 2004;126(0012-3692):659.
22. Spencer S, Calverley PM, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001;163(1):122-8.
23. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal 2004;23(5):698-702.
24. Borgstrom L, Asking L, Olsson H, Peterson S. Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004:C22 Poster 505.
25. Calverley PM, Bonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal 2003;22(6):912-9.
26. Calverley PMA. Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax 2002;57 Suppl III:iii44.
27. Calverley PMA, Cseke Z, Peterson S. Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P436.
28. Calverley PMA, Kuna P, Olsson H. COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P1587.
29. Calverley PMA, Olsson H, Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono-components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 418.
30. Calverley PMA, Peterson S. Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D092 Poster 211.
31. Calverley PMA, Stahl E, Jones PW. Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:B93 Poster 303.
32. Calverley PMA, Szafranski W, Andersson A. Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD. European Respiratory Journal 2005;26 Suppl 49:Poster 1917.
33. Calverley PMA, Thompson NC, Olsson H. Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P435.
34. Halpin D, Ståhl E, Lundback B, Anderson F, Peterson S. Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004:D22 Poster 525.
35. Halpin DMG, Larsson T, Calverley PMA. How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego. 2005:B93 Poster 314.
36. Jones PW, Ståhl E. Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 419.
37. Jones PW, Ståhl E. Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1352.
38. Jones PW, Ståhl E. Reducing exacerbations leads to a better health-related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1586.
39. Lofdahl CG. Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review 2004;13(88):14-21.
40. Lofdahl CG, Andreasson E, Svensson K, Ericsson A. Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal 2003;22(Suppl 45):P433.
41. Lofdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono-component used alone. Pharmacoeconomics 2005;23(4):365-75.
42. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361(9356):449-56.
43. Calverley PMA, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al.Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal 2002;20(Suppl 38):242s [P1572].
44. Calverley PMA, Pauwels RA, Vestbo J, Jones PW, Pride NB, Gulsvik A, et al.Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012).
45. Calverley PMA, Pauwels RA, Vestbo J, Jones PW, Pride NB, Gulsvik A, et al.Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts-on-line.com/abstracts/ATS (accessed 20 April 2012).
46. Hunjan MK, Chandler F. Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando. 2004:D22 Poster 503.
47. Hunjan MK, Williams DT. Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal 2004;24 Suppl 48:291s.
48. Hunjan MK, Williams DT. Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal 2004;24 Suppl 48:513s.
49. Jones PW, Edin HM, Anderson J. Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts-on-line.com/abstracts/ATS (accessed 21 April 2012).
50. Jones PW, Ståhl E. Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 1352.
51. Jones PW, Vestbo J, Pauwels RA, Calverley PMA, Anderson JA, Spencer MD. Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna. 2003:P1593.
52. Nitschmann S. Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist 2004;45(6):727-8.
53. Pauwels RA, Calverly PMA, Vestbo J, Jones PW, Pride N, Gulsvik A, et al.Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal 2002;20 Suppl 38:240 [P1569].
54. Pauwels RA, Vestbo J, Calverley PMA, Jones PW, Pride NB, Gulsvik A. Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012).
55. SFCB3024. A multi-centre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012).
56. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23(6):619-37.
57. Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal 2004;24 Suppl 48:290s.
58. Vestbo J, Calverley PMA, Pauwels R, Jones P, Pride N, Gulsvik A, et al.Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal 2002;20 Suppl 38:240 [P1570].
59. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005;60(4):301-4.
60. Vestbo J, Pauwels RA, Calverley PMA, Jones PW, Pride NB, Gulsvik A. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012).
61. Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine 2004;98(11):1045-50.
62. Allegra L. TORCH study: An invitation to clinical considerations. GIMT - Giornale Italiano delle Malattie del Torace 2007;61(1):15-23.
63. Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, et al.Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal 2010;35(3):532-9.
64. Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health 2006;9(4):227-35.
65. Calverley P, Celli B, Anderson J, Ferguson G, Jenkins C, Jones P, et al.Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on-treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15-20; San Diego. 2009:A6191[Poster #219].
66. Calverley P, Celli B, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al.The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology 2006;11 Suppl 5:A149 [PS-3-8].
67. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
68. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65(8):719-25.
69. Calverley PM, Celli B, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al.The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest 2006;130(4):122s.
70. Calverley PMA, Celli B, Andersen JA, Ferguson GT, Jenkins C, Jones PW, et al.The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal 2006;28 Suppl 50:34.
71. Celli B, Calverley PM, Anderson JA, Ferguson GT, Jenkins C, Jones P, et al.The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology 2006;11 Suppl 5:A140.
72. Celli B, Calverley PM, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al.The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest 2006;130(4):177s.
73. Celli B, Calverley PMA, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al.The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal 2006;28 Suppl 50:34s [E312].
74. Celli B, Emmett A, Crater G, Kalberg C. Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2-6; Munich. 2006:A320 (Poster 323).
75. Celli B, Ferguson GT, Anderson JA, Jenkins CR, Jones PW, Vestbo J, et al.Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763.
76. Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PMA, et al.Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine 2011;183(3):317-22.
77. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine 2008;178(4):332-8.
78. Celli D, Emmett A, Crater G, Kalberg C. Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal 2006;28 Suppl 50:764 [4395].
79. Corhay JL, Louis R. Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege 2007;62(4):230-4.
80. Ferguson GT, Calverley PM, Anderson JA, Celli B, Jenkins C, Jones PW, et al.The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest 2006;130(4):178s.
81. Ferguson GT, Calverley PM, Anderson JA, Celli B, Jenkins CR, Jones PW, et al.Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A763.
82. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Celli B, et al.Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest 2009;136(6):1456-65.
83. Ferguson GT, Calverley PMA, Anderson JA, et al.The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal 2006;28 Suppl 50:34s.
84. Glick H, Briggs A, Lozano-Ortega G, Spencer M, Vestbo J, Calverley P. Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:[C97].
85. Jenkins C, Celli B, Anderson J, Ferguson G, Calverley P, Jones P, et al.Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15-20; San Diego. 2009:A6186 [Poster #213].
86. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al.Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal 2012;39:38-45.
87. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al.The TORCH survival study: consistent efficacy results seen in geographic regions in a multi-national study [Abstract]. American Thoracic Society International Conference; May 18-23; San Francisco. 2007:[C97].
88. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al.Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research 2009;10:59.
89. Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, et al.Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research 2011;12:71.
90. Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Jenkins C, et al.The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest 2006;130(4):177s.
91. Jones PW, Vestbo J, Anderson JA, Celli B, Ferguson GT, Jenkins CR, et al.Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:[C97].
92. Keene ON, Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, et al.Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal 2009;34(5):1018-23.
93. McDonough C, Blanchard AR. TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice 2010;38(2):92-3.
94. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, Committee TCE et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62(5):411-5.
95. Mehta RS, Kathman SJ, Daley-Yates PT, Cahn T, Beerahee M, Kunka RL, et al.Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #A41.
96. SCO30003. A multi-centre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012).
97. Sacchetta A. Long term therapy and outcome of chronic obstructive pulmonary disease with or without co-morbidity: The TORCH Study. Italian Journal of Medicine 2008;2(3):11-5.
98. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al.Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal 2011;5(1):44-9.
99. Vestbo J, TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal 2004;24(2):206-10.
100. Calverley PMA, Kuna P, Monso E, Costantini M, Petruzzelli Sd, Sergio F, et al.Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine 2010;104:1858-68.
101. Choudhury AB, Dawson CM, Kilvington HE, Eldridge HE, James WY, Wedzicha JA, et al.Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care - a randomised controlled trial [Abstract]. European Respiratory Journal 2005;26 Suppl 49:Abstract No. 1328.
102. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, et al.Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respiratory Research 2007;8:93.
103. Dal Negro R, Micheletto C, Trevsian F, Tognella S. Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. American Thoracic Society 98th International Conference; May 17-22; Georgia. 2002.
104. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & fluticasone 50 mcg/250 mcg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics 2003;16(4):241-6.
105. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al.Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbation of COPD: two replicate double-blind, parallel-group, randomised controlled trials. The Lancet: Respiratory Medicine 2013;1(3):210-23.
106. Dalal AA, Blanchette CM, Petersen H, Manavi K, St. Charles M. Cost-effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double-blind, parallel-group, multi-centre trial (Study SCO40043) [Abstract]. Chest 2008;134(4):106003s.
107. Ferguson G, Anzueto A, Fei R, Emmett A, Crater G, Knobil K, et al.A randomized, double-blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest 2007;132(4):530b-531.
108. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respiratory Medicine 2008;102:1099-108.
109. SCO40043. A randomized, double-blind, parallel-group, 52-week study to compare the effect of fluticasone propionate/salmeterol DISKUS® 250/50mcg bid with salmeterol DISKUS® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://ctr.gsk.co.uk (accessed 8 April 2008).
110. Fukuchi Y, Samoro R, Fassakhov R, Taniguchi H, Ekelund J, Carlsson LG, et al.Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results. Respirology 2013; Vol. 18:866-73.
111. Ichinose M, Samoro R, Fassakhov R, Oguri M, Ekelund J, Carlsson LG, et al.Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results [Abstract]. European Respiratory Society Annual Congress; 2012 Sep 1-5; Vienna. 2012; Vol. 40, issue Suppl 56:374s [P2108].
112. FCO30002. A multi-centre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with Salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register (accessed 15 April 2012).
113. FLTA3025. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline Clinical Trial Register (accessed 18 April 2012).
114. SCO100470. A multi-centre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). http:ctr.gsk.co.uk (accessed 20 April 2012).
115. Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk-clinicalstudyregister.com/ 2008 (accessed 19 April 2012).
116. SCO104925. Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012).
117. SCO30002. A multi-centre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 μg two puffs bd and fluticasone propionate 250μg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. GlaxoSmithKline Clinical Trial Register (accessed 21 April 2012).
118. NCT00355342. A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Via DISKUS Versus Salmeterol 50mcg BID Via DISKUS on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD). http://clinicaltrials.gov/show/NCT00355342 (accessed 19 April 2012).
119. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al.The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124(3):834-43.
120. Hanania NA, Knobil K, Watkins M, Wire P, Yates J, Darken P. Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest 2002:S129.
121. Hanania NA, Ramsdell J, Payne K, Davis S, Horstman D, Lee B, et al.Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine 2001;163 Suppl 5:A279.
122. Horstman D, Darken P, Davis S, Lee B. Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P434.
123. Mahler DA, Darken P, Brown CP, Knobil K. Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14-15; Arlington. 2003:1081.
124. Mahler DA, Darken P, Brown CP, Knobil K. Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P429.
125. SFCA3007. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012).
126. Spencer M, Wire P, Lee B, Chang CN, Darken P, Horstman D. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal 2003;22 Suppl 45:51s.
127. Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal 2004;24 Suppl 48:290s.
128. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57(9):799-803.
129. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2002;165(12):1592-9.
130. Kardos P, Wencker M. Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD. European Respiratory Journal 2005;26 Suppl 49:Abstract 1944.
131. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2007;175(2):144-9.
132. SCO30006. A randomised, double-blind, parallel-group study to investigate the protective effect of the combination of fluticasone and salmeterol (500/50 μg bid via the DISKUS) compared with salmeterol (50 μg bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) (GOLD III/IV). http:ctr.gsk.co.uk (accessed 21 April 2012).
133. Vogelmeier C. Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QoL) more than salmeterol (SAL) alone in COPD. 42nd Nordic Lung Conference; 2005 Jun 9-11; Trondheim. 2005; Vol. 13 Suppl 22.
134. Vogelmeier CF, Wencker M, Glaab TH, Kardos P. Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment.. American Thoracic Society International Conference; May 19-21; San Diego. 2006:A110.
135. Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, et al.A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine 2013; Vol. 107, issue 4:560-9. [: 0954-6111].
136. Kerwin EM, Scott-Wilson C, Sanford L, Rennard SI, Agusti A, Barnes N, et al.Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1-5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082].
137. Kunz LIZ, Strebus J, Budulac SE, Lapperre TS, Sterk PJ, Postma DS, et al.Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial. PloS one 2013; Vol. 8, issue 5:e63430.
138. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, et al.Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine 2009;151(8):517-27.
139. Laptseva IM, Laptseva EA, Borshchevsky VV, Gurevich G, Kalechits O. Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal 2002;20 Suppl 38:244s.
140. Mahler DA, Darken P, Brown CP, Knobil K. Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012).
141. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al.Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2002;166(8):1084-91.
142. SFCA3006. A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012).
143. Spencer M, Wire P, Lee B, Chang CN, Darken P, Horstman D. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal 2003;22 Suppl 45:51.
144. Spencer MD, Anderson JA. Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005:B93 [Poster 308].
145. Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal 2004;24 Suppl 48:290.
146. Martinez F, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, et al.Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid-high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1-5. 2012; Vol. 40, issue Suppl 56:527s [P2887].
147. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, et al.Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine 2013;107(4):550-9. [: 0954-6111].
148. Mirici A, Bektas Y, Ozbakis G, Erman Z. Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation 2001;21(12):835-42.
149. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respiratory Medicine 2005;99(12):1494-500.
150. FLIT97. A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 μg daily with placebo in chronic obstructive pulmonary disease. http://ctr.gsk.co.uk (accessed 20 April 2012).
151. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351(9105):773-80.
152. Johnell O, Pauwels R, Löfdahl C-G, Laitinen LA, Postma DS, Pride NB, et al.Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal 2002;19(6):1058-63.
153. Lofdahl CG, Postma DS, Laitinen LA, Ohlsson SV, Pauwels RA, Pride NB. The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine 1998;92(3):467-72.
154. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al.Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 1999;340(25):1948-53.
155. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal 1992;5(10):1254-61.
156. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109(5):1156-62.
157. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al.Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54(1):7-14.
158. Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, et al.ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest 2012; Vol. 142, issue 2:320-8.
159. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al.Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1-year randomized controlled clinical trial. Drugs 2009;69(5):549-65.
160. Chavannes NH, Schermer TR, Wouters EF, Akkermans RP, Dekhuijzen RP, Muris JW, et al.Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD 2009;4:431-6.
161. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al.Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine 2009;103(4):542-51.
162. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Norgaard M, Nielsen C, et al.Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine 1999;93(10):715-8.
163. Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, et al.The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;6(2):104-11.
164. Shaker SB, Stavngaard T, Laursen LC, Stoel BC, Dirksen A. Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2011;8(1):2-7.
165. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respiratory Medicine 2012;106(2):257-68.
166. Sharafkhaneh A, Uryniak T, Martin U. Long-term effects of budesonide/formoterol pressurized metered-dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest 2011;140(4):528A.
167. Anderson P. Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax 2002;57 Suppl 3:iii43.
168. Borgstrom L, Asking L, Olsson H, Peterson S. Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21-26; Orlando. 2004:C22 [Poster 505].
169. Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, et al.Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal 2005;26(3):406-13.
170. Calverley PMA. Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax 2002;BTS Winter Meeting 2002:S145.
171. Calverley PMA, Szafranski W, Andersson A. Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD. European Respiratory Journal 2005;26 Suppl 49:Poster 1917.
172. Calverley PMA, Thompson NC, Olsson H. Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal 2003;22 Suppl 45:P435.
173. Campbell LM, Szafranski W. Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143.
174. Campbell LW, Szafranski W. Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141.
175. Dahl R, Cukier A, Olsson H. Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal 2002;20 Suppl 38:242 [P1575].
176. Egede F, Menga G. Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study. European Respiratory Journal 2002;20 Suppl 38:242 [P1574].
177. Halpin D, Stahl E, Lundback B, Anderson F, Peterson S. Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21-26; Orlando. 2004:D22 Poster 525.
178. Jones PW, Stahl E, Svensson K. Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal 2002;20 Suppl 38:250 [P1613].
179. Korsgaard J, Sansores R. Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD. European Respiratory Journal 2002;20 Suppl 38:242 [P1577].
180. Lange P, Saenz C. Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal 2002;20 Suppl 38:242 [P1573].
181. Lofdahl CG. Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review 2004;13(88):14-21.
182. Milanowski J, Nahabedian S. Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal 2002;20 Suppl 38:242 [P1576].
183. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal 2003;21:74-81.
184. Szfranski W, Ramirez A, Peterson S. Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14-18; Stockholm. 2002.
185. AstraZeneca. A 6-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy & safety study of SYMBICORT® pMDI 2 x 160/4.5 μg & 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (& the combination) & placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012).
186. Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, et al.Effect of ß2-Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered-Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183:A4086.
187. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68(14):1975-2000.
188. van Grunsven P, Schermer T, Akkermans R, Albers M, van den Boom G, van Schayck O, et al.Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respiratory Medicine 2003;97(12):1303-12.
189. Verhoeven GT, Garrelds IM, Hoogsteden HC, Zijlstra FJ. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation 2001;10(1):21-6.
190. Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects of fluticasone propionate in COPD patients with bronchial hyper-responsiveness. Thorax 2002;57(8):694-700.
191. Verhoeven GT, Wijkhuijs AJ, Hooijkaas H, Hoogsteden HC, Sluiter W. Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation 2000;9(2):109-13.
192. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353(9167):1819-23. [MEDLINE: 99285938].
193. Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology 2004;9(3):352-5.
194. GlaxoSmithKline F. A single-centre, double-blind study to investigate the effects of inhaled fluticasone propionate (FP) 1500mcgdaily on inflammatory processes in the lungs of patients with chronic obstructive airways disease [FLIP63]. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
195. GSK SAM30022. A phase IV, multi-centre, double-blind, double-dummy, parallel group, randomised study comparing Seretide (25/50 2 puffs bd) via the Evohaler (MDI-HFA) with Beclometasone dipropionate (200mcg 2 puffs bd) via the MDI-CFC in adolescents and adults experiencing moderate symptoms of reversible airways obstruction. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
196. GSK SAM40004. A multi-centre, randomised, double-blind, placebo-controlled parallel group study to compare the effect on airway inflammation and remodelling of treatment with salmeterol/fluticasone propionate combination product (50/100μg strength) bd via the Accuhaler inhaler, or fluticasone propionate 100μg bd via the Accuhaler inhaler or placebo via the Accuhaler inhaler for 16 weeks, followed by double-blind treatment for 52 weeks with the salmeterol/fluticasone propionate combination product (50/100μg strength) bd via the Accuhaler inhaler or fluticasone propionate 100μg bd via the Accuhaler inhaler, in adults with reversible airways obstruction (SIRIAS - Seretide in Inflammation and Remodelling In Asthma Study). www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
197. GSK SAS40015. A multi-centre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100 mcg strength) bd via the DISKUS/ACCUHALER inhaler with fluticasone propionate (100 mcg strength) bd via the DISKUS/ACCUHALER inhaler plus oral montelukast 10 mg od in adolescents and adults with reversible airways obstruction [SAS40015]. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
198. GSK SCO100540. A multi-centre, randomised, double-blind, parallel group study to investigate the efficacy and safety of the Salmeterol/fluticasone propionate combination at a strength of 50/500μg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
199. GSK SCO100646. Clinical Evaluation of SFC for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) -Assessment of the Effect of Addition of Fluticasone Propionate to Salmeterol Xinafoate 50 mcg after Switching under Double-blinded Conditions to SFC 50/250 mcg in Chronic Obstructive Pulmonary Disease. Study number SCO100646. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
200. GSK SCO30005. A 13-week, double-blind, parallel-group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/ fluticasone propionate (SERETIDE™/ADVAIR™/VIANI™) 50/500 mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease [SCO30005]. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
201. GSK SCO40030. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID via DISKUS and Salmeterol 50mcg BID via DISKUS on Lung Hyperinflation in Subjects with Chronic Obstructive Pulmonary Disease (COPD). [SCO40030]. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
202. GSK SCO40034. A multi-centre, randomised, double-blind, double dummy, parallel group 12-week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with Chronic Obstructive Pulmonary Disease (COPD). www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
203. GSK SCO40036. Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily via the DISKUS*/ACCUHALER* Inhaler with Tiotropium Bromide 18 mcg Delivered Once Daily via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects with Severe Chronic Obstructive Pulmonary Disease (COPD). www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
204. GSK SCO40036. Multicentre, randomised, double-blind, double-dummy, parallel group, 104-week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk-clinicalstudyregister.com (accessed 8 April 2012).
205. GSK SFCB3019. A multi-centre randomized, double-blind, double-dummy, parallel-group comparison of the salmeterol/fluticasone propionate combination product (50/500mcg strength) BD via one DISKUS/Accuhaler inhaler with salmeterol 50mcg BD via one DISKUS/Accuhaler and fluticasone propionate 500mcg BD via another DISKUS/Accuhaler and with fluticasone propionate 500mcg BD via one DISKUS/Accuhaler in adolescents and adults with reversible airways obstruction. www.gsk-clinicalstudyregister.com (accessed 20 April 2012).
206. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine 2000;343(26):1902-9.
207. Monninkhof E, van der Valk P, van der Palen J, Zielhuis G, van Hervaarden C, Van Herwaarden C. Effect of discontinuation of inhaled steroids on health-related quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2002;165 Suppl 8:A226.
208. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C, van der Phalen J. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. American Journal of Respiratory and Critical Care Medicine 2002;166(1073-449X):1358-63.
209. van der Valk P, Monninkhof EM, van der Palen JAM, Zielhuis GA, van Herwaarden CLA. Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD. European Respiratory Journal 2001;18 Suppl 33:183s.
210. Weir DC, Bale GA, Bright P, Sherwood Burge P. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy 1999;29(Suppl 2):125-8.
211. Wouters EF. COPD and Seretide: a multi-centre intervention and characterisation (COSMIC) study: a rationale and baseline characteristics [abstract]. European Respiratory Society Annual Congress; Sep 14-18; Stockholm. 2002:P1571.
212. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al.Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7.
213. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AFTCC, et al.[Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial]. [Portuguese]. Revista Portuguesa de Pneumologia 2005;11(6):587-9.
214. Ohar JA, Crater G, Emmett A, Ferro T, Morris A, Raphiou I, et al.Effects of Fluticasone Propionate/Salmeterol Combination 250/50mcg BID (ADVAIR DISKUS™) vs. Salmeterol 50mcg BID (SEREVENT DISKUS™) on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate, Following Acute Exacerbation or Hospitalization. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187(Meeting Abstracts):A2439.
215. Vestbo J, Anderson J, Brook RD, Calverley PMA, Celli BR, Crim C, et al.The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal 2013;41(5):1017-22. [: 0903-1936].
216. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations. Chest 2010;137(2):318-25.
217. Agusti A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, et al.A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. The European Respiratory Journal. 2013/10/12 2013 Oct 10 [Epub ahead of print]. [1399-3003: (Electronic)].
218. American Thoracic Society / European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2. http://www.thoracic.org/go/copd. New York: American Thoracic Society, (accessed 4 May 2012). [URL: http://www.thoracic.org/go/copd].
219. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clinical Therapeutics 2010;32(7):1320-8.
220. British Thoracic Society, Community Acquired Pneumonia in Adults Guideline Group. Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl III):iii1-iii55.
221. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997; Vol. 50, issue 6:683-91. [0895-4356: (Print)].
222. Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 2013;68(6):499-500.
223. Cipriani A, Higgins JPT, Geddes JR, Salanti GS. Conceptual and technical challenges in network meta-analysis. Annals of Internal Medicine 2013;159(2):130-7.
224. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-16. [1538-3598: (Electronic)].
225. Effing T, Monninkhof EEM, van der Valk PPDLPM, Zielhuis GGA, Walters EH, van der Palen JJ, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2].
226. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. American Journal of Respiratory and Critical Care Medicine 2007;176:162-6.
227. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al.Indirect comparisons of competing interventions. Health Technology Assessment 2005;9(26):1-134, iii-iv. [1366-5278: (Print)].
228. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 22 November 13).
229. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. International Journal of Clinical Practice 2011;65(7):764-74. [1742-1241: (Electronic)].
230. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane-handbook.org.
231. Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al.Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013/05/31 2013; Vol. 346:f3306. [1756-1833: (Electronic)].
232. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. Journal of Allergy and Clinical Immunology 1998;101(4):S434-9.
233. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2].
234. Marzoratti L, Iannella HA, Waterer GW. Inhaled corticosteroids and the increased risk of pneumonia. Therapeutic Advances in Respiratory Disease. 2013/03/01 2013; Vol. 7, issue 4:225-34. [1753-4666: (Electronic)].
235. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2].
236. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4].
237. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 4 February 2012). [URL: http://guidance.nice.org.uk/CG101/CostingReport/pdf/English].
238. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Therapeutic Advances in Respiratory Disease 2009;3(4):147-57.
239. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3].
240. Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. Journal of Medical Economics 2011;14(6):769-76.
241. Rossios C, To Y, To M, Ito M, Barnes PJ, Adcock IM, Johnson M, Ito K. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. European Journal of Pharmacology 2011;670(1):244-51.
242. Ruiz Garcia V, Compte Torrero L. [Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients]. Medicina Clinica. 2011/03/15 2011; Vol. 137, issue 7:302-4. [0025-7753: (Print)].
243. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al.Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374(9691):712-9. [1474-547X: (Electronic)].
244. Singanayagam A, Chalmers J, Hill A. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. Quarterly Journal of Medicine 2010;103:379-85.
245. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine 2009;169(3):219-29. [1538-3679: (Electronic)].
246. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. Journal of Clinical Epidemiology 2008;61(5):455-63. [0895-4356: (Print)].
247. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-36.
248. Van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999].
249. World Health Organization. Chronic respiratory diseases. http://www.who.int/respiratory/en/ (accessed 7 February 2012).
250. Yang IA, Fong K, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002991.pub2].
251. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews. 2012/07/13 2012; Vol. 7:CD002991. [1469-493X: (Electronic)].
252. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2013/07/10 2013; Vol. 8:295-304. [1178-2005: (Electronic)].